Novel Microdevices
Latest round
- Series A
Last raised
- Feb 2025
Total raised
- $0.5M
Investors
- 2
About Novel Microdevices
In February 2025, Novel Microdevices, Inc. The firm develops and commercializes its proprietary Point-of-Care (POC) rapid molecular diagnostics system called Novel Dx that implements polymerase chain reaction (PCR) technology on a disposable cartridge to diagnose the genetic sequence of cells to identify the disease and the presence of genetic mutations that makes bacteria resistant to antibiotics. The firm diagnoses sexually transmitted bacterial infections, including Chlamydia trachomatis and Neisseria gonorrhoeae using vaginal swabs or urine samples.
Who invested in Novel Microdevices
2 investors across 1 round
See all investors in Novel Microdevices
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Feb 18, 2025
Amount
$0.5M
Investors
Questions about Novel Microdevices
Who invested in Novel Microdevices?
Novel Microdevices has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Novel Microdevices raised?
Novel Microdevices has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Novel Microdevices last raise money?
Novel Microdevices's most recent round on record is a Series A, in Feb 2025.
What does Novel Microdevices do?
In February 2025, Novel Microdevices, Inc.
Where is Novel Microdevices headquartered?
Novel Microdevices is headquartered in Baltimore, US.
Which VCs invest in companies like Novel Microdevices?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back medical devices & equipment companies at Novel Microdevices's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series A
Raising like Novel Microdevices? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.